- Revenue for the quarter was ₹341 Cr. Gross margin for the quarter was 42.4% (compared to 48.1% Q1 FY22). EBITDA margin pre-ESOP 5.9% (compared to 11.2% Q1 FY22) and post-ESOP EBITDA margin of 3.2% (compared to 6.3% Q1 FY22).
- Revenue from API for the quarter was ₹88.8Cr (2.5% decline YOY). API momentum was impacted due to the fire incident in May. The plant is back online and management has said this is only a quarterly impact and shouldn’t affect API revenues for the full year. The impact is of ₹14-15 Cr which will spill over into the other quarters.
- Formulations revenue was ₹244.8 Cr (7.9% growth YOY). They are facing issues on account of volatile currencies but they have been able to increase market share during the quarter.
- Growth in formulations has come from good sales momentum in Latam. Performance in India was also strong.
- Input costs for both APIs and formulations have stabilized to some extent along with costs for utilities and logistics, but they still remain at elevated levels.
- Inflation in Turkey has exceeded 100% over the last 3 years. Therefore, IND AS 29 (Accounting for hyperinflationary economies) has been triggered. Financial statements for Turkish subsidiaries have been prepared in accordance with these standards. Impact on the consolidated PAT is ₹95 lakhs.
- Management has said that demand for their products in Turkey seems to be strong. They are trying to hedge the currency impact by increasing exports to Europe.
- The integration of the Nourrie acquisition is going well.
- Revenues from the CDMO contract are expected to start towards the end of FY23 and the full impact is expected in FY24. They have added 1 more molecule to the CDMO pipeline and are in talks with customers to add more. They have enough API capacity for the next 2 years.
- 65-70% of the API business comes from regulated markets. They have entered into long term contracts in these markets and can only pass on price increases when the contract expires.
- The Albendazole supply to WHO has stabilized. The demand for Albendazole for Animal Health is stable, but very competitive in terms of pricing.
- Their API portfolio consists of older generics where they get into long term contracts with multinational companies and newer molecules where they are approaching multinationals and CDMO for innovators.
- They have a stronger position in formulations where their products are branded. They are able to pass on price increases in markets where the dealers don’t hold a lot of inventory.
- The Brazil formulations business is based on long term contracts with large farms.
- For their European business, they do not see any impact on the demand for their products. They do not foresee any cut back in production due to the energy crisis in Europe.
- Management has guided that they will come close to their guidance for the full year which is 100-150 bps improvement in margin over last year and mid teens growth in revenues.
